PharmaTher Holdings Ltd · CSE:PHRM
PharmaTher — Investor Presentation (November 2026)
28 slides from PharmaTher's investor presentation, November 2026
Slide 1: 3D Printed Personalized Medicine
3D Printed Personalized Medicine pharmather.com Corporate Presentation · November 2026 CSE: PHRM | OTCQB: PHRRF
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-looking information, incl
Slide 3: Pharmaceutical 3D Printing for Personalized Medicine
Pharmaceutical 3D Printing for Personalized Medicine M3DICINES Platform ±1% dose precision CraftMake 3D printer · Novel formulations No heat no UV · room temperature PERSONALIZ3D Peptides Gummy and Tablet (BPC-157 and KPV) · NAD+ Gummy GMP-ready enclosed · dual printheads CraftMake by Craft Health P
Slide 4: Our Mission: Medicine is made for everyone. We make it for one.
Our Mission Medicine is made for everyone. We make it for one. CSE: PHRM | OTCQB: PHRRF
Slide 5: Market Opportunity: A large market that mass production cannot serve
Market Opportunity → A large market that mass production cannot serve Personalized medicine is growing. The exact dose, for one patient, is what 3D printing can make $567B → $1.2T $141B → $295B Personalized-medicine market, 2024 → 2033 Peptide therapeutics market, 2025 → 2033 The Problem The Solutio
Slide 6: Why 3D Printing of Medicines
Why 3D Printing of Medicines Five things mass pharmaceutical production can not do economically. M AS S PRO D U CTIO N 3 D PRIN TING Batch size Pays off only at millions of units → Economic from tens to thousands of units Dose A few fixed strengths; patients split pills → Any dose, ±1% accurate, fro
Slide 7: Our Solution
Our Solution CSE: PHRM | OTCQB: PHRRF
Slide 8: M3DICINES 3D-Printed Medicines Platform
M3DICINES 3D-Printed Medicines Platform Precise, room-temperature (no heat, no UV) printing of customized doses on GMP-ready CraftMake . CR AFT MAKE 3 D P R I NT E R DO SAG E FO RM S Pellets & mini-tablets Dual-print tablets Gummies & chewables Multi-layered tablets C RA F TC O N T RO L SO F T WA R
Slide 9: Exclusive North American Rights to CraftMake
Exclusive North American Rights to CraftMake 10,000+ potential sites across North America. P OTEN TIAL PARTNERS & CU STOMERS Every placement is infrastructure, not a one-time sale. 503A compound pharmacies ~7,500 U.S. 503A pharmacies alone Each system keeps earning. Telehealth and consumer health Wh
Slide 10: Business Model
Business Model Our moat: exclusive CraftMake rights plus our own formulations and data, made possible only by 3D printing. TELEHEALTH PARTNERING We sell our printed peptides, direct and through partners. We put the platform to work for others. Peptide gummies In-house placements Heat-free gummies, d
Slide 11: Our Programs
Our Programs CSE: PHRM | OTCQB: PHRRF
Slide 12: Peptides and Longevity
Peptides and Longevity Peptides and NAD+/NMN in a gummy, dosed for one patient, with no heat and no UV. G UMMY T A B LE T P E LL E T Peptide Longevity Gummy BPC-157 · KPV · gummy, tablet or pellet NAD+ and NMN in one gummy, two layers Layered, single-dose or core-and-shell gummies, printed at 25°C w
Slide 13: Colon-targeted peptides: first in line for a new U.S. peptide market
Colon-targeted peptides: first in line for a new U.S. peptide market HHS opened a peptide pathway in Oct. 2026; only KPV and BPC-157 are covered for oral use. O U R O P P O R TU N IT Y , O U R M O A T HO W IT W O RKS · A P I LL - IN - P IL L T HA T O P EN S I N T HE C O L O N A new market just opene
Slide 14: FDA program: GAMT Deficiency, a rare childhood disease with no approved treatment
FDA program: GAMT Deficiency, a rare childhood disease with no approved treatment 3D-printed creatine; approval could earn a priority review voucher worth US$150–200M. The disease WHAT A PP RO VA L CA N E AR N Children born unable to make creatine. Untreated: disability and seizures by age three. 7
Slide 15: Additional Product Opportunities
Additional Product Opportunities Too small for a production line, and exactly right for 3D printing. Rare diseases Psychedelic medicines Discontinued & short-supply Patients may need only a few thousand doses a Precisely dosed psilocybin and MDMA, with Medicines dropped because demand got too year,
Slide 16: Telehealth Programs: Unique to our 3D printer technology
Telehealth Programs: Unique to our 3D printer technology Telehealth platforms and pharmacies add a differentiated, documented peptide without building a lab. O U R B R AN D P AR T N E R B R AN DS PERSONALIZ3D Partner telehealth Telehealth site: an online visit, a Telehealth platforms add our printed
Slide 17: Partnership opportunities
Partnership opportunities CSE: PHRM | OTCQB: PHRRF
Slide 18: Ways to work with us
Ways to work with us Three ways in, one platform: every partner adds recurring revenue. 50 3A P HA R M AC I E S C DM O S E R V IC E S B U S I N E S S D E V E LO P M E N T Bring 3D printing in-house Let us make it Build a product together For pharmacies, hospitals, CDMOs and labs. For telehealth, pha
Slide 19: Strategic Assets: Monetization outside the 3D printing core
Strategic Assets: Monetization outside the 3D printing core Ketamine ANDA payments expected from Q1 2027. Other assets available to license, sell, partner or spin out. Ketamine ANDA KetaVault Ketamine patch KetaMist® Sairiyo (49%) >US$25M 5 40 h 9,000+ US$3.5M potential over time: milestones orphan
Slide 20: An asset-light model with three partners, already in place
An asset-light model with three partners, already in place TEC HNO LO GY DISP ENSI NG A ND R&D M A N U F A CT U R I N G Exclusive North American distributor Center of Excellence GMP contract manufacturer CraftMake systems, software, materials and service. PD Labs: a U.S. national 503A compounding FD
Slide 21: Future Opportunities
Future Opportunities CSE: PHRM | OTCQB: PHRRF
Slide 22: Our Vision of a M3DICINES Network for National Emergencies
Our Vision of a M3DICINES Network for National Emergencies Commercial work in peacetime. Countermeasures in an emergency. 1 · Validate and qualify We validate the recipes; each partner installs CraftMake and is qualified and trained. 2 · Peacetime Nodes print for patients, our products, partners and
Slide 23: Future Telehealth Programs
Future Telehealth Programs Only 3D printing can make these: any dose, any form, made for one patient. Pediatrics Dysphagia Deprescribing (tapering off) Children are dosed by weight, but medicines come in People with Parkinson's, ALS or stroke crush, split or skip Coming off an antidepressant takes d
Slide 24: Future Product Partnership Programs
Future Product Partnership Programs Partners bring the customers and the brand; we bring the printed product. Nutraceuticals Pet health Repurposed & reformulated Vitamins and supplements in layered gummies and Pets need doses matched to their weight, in a form they New forms of FDA-approved drugs, s
Slide 25: Expected Milestones: the next 12 months
Expected Milestones: the next 12 months Product launches, commercial and partnering sales and FDA decisions. Q4 2026 – 2027 Q1 2027 2027 CraftMake placements in 503A First ketamine ANDA payments Licensing, sale or spin-out of pharmacies strategic assets 2 4 6 1 3 5 From Q4 2026 Q1 2027 2027 PERSONAL
Slide 26: Leadership across drug development, FDA approvals, compound pharmacy, commercialization, and manufacturing
Leadership across drug development, FDA approvals, compound pharmacy, commercialization, and manufacturing MANAGEMENT & BOA RD CS Fabio Chianelli Carmelo Marrelli Dr. Beverly J. Incledon Carlo Sansalone Founder, Chairman & CEO Chief Financial Officer Director Director 25+ years in specialty life sci
Slide 27: Capital structure
Capital structure As at September 30, 2026 91,019,065 1,500,000 ~19% Issued and outstanding common shares Stock options outstanding Insider ownership PHRM (CSE) PHRRF (OTCQB) COMPANY F ACTS Transfer agent Auditor Fiscal year-end Filings Marrelli Trust Company Limited Truster Zweig Raithatha (TZR) Ju
Slide 28: Thank You
Thank You info@pharmather.com · 1-888-846-3171 pharmather.com CSE: PHRM | OTCQB: PHRRF
PharmaTher Holdings — Investor Presentation (November 2026) on 6ix